Arca Biopharma (NASDAQ:ABIO) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.86) by $0.72, Fidelity Earnings reports.
ABIO traded down $0.23 during trading on Friday, reaching $6.12. 51,469 shares of the company traded hands, compared to its average volume of 47,922. Arca Biopharma has a 12-month low of $4.68 and a 12-month high of $20.45. The business’s fifty day simple moving average is $6.85.
A number of equities research analysts have issued reports on the stock. ValuEngine raised shares of Arca Biopharma from a “hold” rating to a “buy” rating in a report on Thursday. Ascendiant Capital Markets set a $17.00 price objective on shares of Arca Biopharma and gave the company a “buy” rating in a report on Tuesday, May 14th.
ARCA biopharma, Inc is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF).
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.